They are also consistent with numerous studies that have demonstrated the efficacy HMG-CoA reductase inhibitors (statins) in reducing the severity of pulmonary hypertension in both chronic hypoxia and monocrotaline animal models [39–44], although contradictory results have also been observed [45]. This evidence concerns the gene HMGCR and pulmonary arterial hypertension.